Overall, mutation-specific IHC for E746_A750 deletion and L858R point mutations in EGFR is highly reliable, with the promise to constitute a rapid screening assay for mutations in individuals with NSCLC, also predicting gefitinib therapeutic efficacy for EGFR mutant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.